Zeus Arco
Adult Health · Beaumont, TXNPI 1386134278
Payments from drug & device makers
Across 824 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$2K
- Novo Nordisk$1K
- Amgen$1K
- Biohaven Pharmaceuticals, Inc.$1K
- Bayer$985
- plus $6K from 24 others
What the payments were for
- Consulting fees$1,2007%
- Food & beverage$15,50093%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 163 | $3,078 |
| AstraZeneca | 84 | $1,964 |
| Novo Nordisk | 92 | $1,490 |
| Amgen | 101 | $1,480 |
| Biohaven Pharmaceuticals, Inc. | 3 | $1,252 |
| Bayer | 45 | $985 |
| Merck | 42 | $823 |
| GSK | 46 | $819 |
| Lilly USA, LLC | 39 | $673 |
| Pfizer | 32 | $671 |
| Novartis | 38 | $623 |
| Corcept Therapeutics | 21 | $467 |
| Esperion Therapeutics, Inc. | 16 | $275 |
| Daiichi Sankyo Inc. | 17 | $273 |
| Exact Sciences | 11 | $230 |
| Amarin Pharma, Inc. | 11 | $220 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $193 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $192 |
| Astellas Pharma US Inc | 11 | $184 |
| Axsome Therapeutics, Inc. | 8 | $175 |
| Inspire Medical Systems, Inc. | 2 | $172 |
| Dexcom, Inc. | 8 | $147 |
| Boehringer Ingelheim | 5 | $117 |
| Lundbeck LLC | 2 | $55 |
| Abbott | 2 | $45 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Eisai Inc. | 1 | $24 |
| Si-bone, Inc. | 1 | $23 |
| Nabriva Therapeutics, PLC | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,726 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $90,480 |
| Repatha SureclickEvolocumab | 92 | $62,409 |
| FarxigaDapagliflozin Propanediol | 34 | $47,930 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $38,622 |
| RybelsusSemaglutide | 13 | $28,298 |
| TradjentaLinagliptin | 16 | $24,946 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $22,262 |
| EliquisApixaban | 15 | $20,100 |
| JardianceEmpagliflozin | 11 | $17,759 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $16,471 |
| MounjaroTirzepatide | 14 | $16,177 |
| LinzessLinaclotide | 18 | $12,951 |
| VerquvoVericiguat | 17 | $12,617 |
| EntrestoSacubitril/Valsartan | 12 | $8,112 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $8,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,490 | $118,77872 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,964 | $86,55390 claims |
| Boehringer IngelheimTradjenta, Jardiance | $117 | $42,70527 claims |
| PfizerEliquis | $671 | $20,10015 claims |
| GSKTrelegy Ellipta | $819 | $16,47121 claims |
| Lilly USA, LLCMounjaro | $673 | $16,17714 claims |
| AbbVieLinzess | $3,078 | $12,95118 claims |
| MerckVerquvo | $823 | $12,61717 claims |
| NovartisEntresto | $623 | $8,11212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.
Other adult health in Beaumont
- Kelly DardenBeaumont$10K
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Cynthia BedellPlano$168K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
- Meghan MurphyAustin$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.